CB2 selective sulfamoyl benzamides: Optimization of the amide functionality

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 309-313

  Goodman, Allan J ^a   Ajello, Christopher W ^a   Worm, Karin ^a   Bourdonnec, Bertrand Le ^a   Savolainen, Markku A ^a   O'Hare, Heather ^a   Cassel, Joel A ^a   Stabley, Gabriel J ^a   DeHaven, Robert N ^a   LaBuda, Christopher J ^a   Koblish, Michael ^a   Little, Patrick J ^a   Brogdon, Bernice L ^a   Smith, Steven A ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

Antiallodynia; Cannabinoid; CB1; CB2; Sulfamoyl benzamides

Indexed keywords

AMIDE; AMINOBENZOTRIAZOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CYTOCHROME P450 INHIBITOR; FUNCTIONAL GROUP; SULFAMOYLBENZAMIDE DERIVATIVE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PAIN; RODENT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ANIMAL; CHEMISTRY; DRUG EFFECT;

RODENTIA;

ANIMALS; BENZAMIDES; PAIN; RECEPTOR, CANNABINOID, CB2; RODENTIA;

EID: 57749115645     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.091     Document Type: Article

References (22)

1. Lambert D.M., and Fowler C.J. J. Med. Chem. 48 (2005) 5059
2. Voth E.A., and Schwartz R.H. Ann. Intern. Med. 126 (1997) 791
3. Pertwee R.G. Prog. Neurobiol. 63 (2001) 569
4. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. Pharmacol. Rev. 54 (2002) 161
5. Quartilho A., Mata H.P., Ibrahim M.M., Vanderah T.W., Porreca F., Makriyannis A., and Malan T.P. Anesthesiology 99 (2003) 955
6. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Vanderah T.W., Lai J., Porreca F., Makriyannis A., and Malan T.P. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10529
7. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottschall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., and Whiteside G.T. Neuropharmacology 48 (2005) 658
8. Omura H., Kawai M., Shima A., Iwata Y., Ito F., Masuda T., Ohta A., Makita N., Omoto K., Sugimoto H., Kikuchi A., Iwata H., and Ando K. Bioorg. Med. Chem. Lett. 18 (2008) 3310
9. Verbist B.M.P., De Cleyn M.A.J., Surkyn M., Fraiponts E., Aerssens J., Nijsen M.J.M., and Gijsen H.J.M. Bioorg. Med. Chem. Lett. 18 (2008) 2574
10. Pagé D., Balaux E., Boisvert L., Liu Z., Milburn C., Tremblay M., Wei Z., Woo S., Luo X., Cheng Y.-X., Yang H., Srivastava S., Zhou F., Brown W., Tamaszewski M., Walpole C., Hdzic L., St-Onge S., Godbout C., Salois D., and Payza K. Bioorg. Med. Chem. Lett. 18 (2008) 3695
11. Ohta H., Ishizaka T., Tasuzuki M., Yoshinaga M., Iida I., Yamaguchi T., Tomishima Y., Futaki N., Toda Y., and Saito S. Bioorg. Med. Chem. 16 (2008) 1111
12. DiMauro E.F., Buchanan J.L., Cheng A., Emkey R., Hitchcock S.A., Huang L., Huang M.Y., Janosky B., Lee J.H., Li X., Martin M.W., Tomlinson S.A., White R.D., Zheng X.M., Patel V.F., and Fremeau Jr. R.T. Bioorg. Med. Chem. Lett. 18 (2008) 4267
13. Ermann M., Riether D., Walker E.R., Mushi I.F., Jenkins J.E., Noya-Marino B., Brewer M.L., Taylor M.G., Amouzegh P., East S.P., Dymock B.W., Gemkow M.J., Kahrs A.F., Ebneth A., Löbbe S., O'Shea K., Shih D.-T., and Thomson D. Bioorg. Med. Chem. Lett. 18 (2008) 1725
14. Worm K., Zhou Q.J., Saeui C.T., Green R.C., Cassell J.A., Stabley G.J., DeHaven R.N., Conway-James N., LaBuda C.J., Koblish M., Little P.J., and Dolle R.E. Bioorg. Med. Chem. Lett. 18 (2008) 2830
15. Chen J.J., Zhang Y., Hammond S., Dewdney N., Ho T., Lin X., Browner M.F., and Castelhano A.L. Bioorg. Med. Chem. Lett. 6 (1996) 1601
16. McBriar M.D., Clader J.W., Chu I., Del Vecchio R.A., Favreau L., Greenlee W.J., Hyde L.A., Nomeir A.A., Parker E.M., Pissarnitski D.A., Song L., and Zhoa Z. Bioorg. Med. Chem. Lett. 18 (2008) 215
17. 1H NMR and LC/MS.
18. 35S]GTPγS binding was determined in the absence of agonist. Generally, the stimulation by 10 μM WIN55212-2 was between 50% and 100% over basal binding. Full agonists stimulate binding to the same maximal extent as WIN55212-2.
19. Halfpenny P.R., Hill R.G., Horwell D.C., Hughes J., Hunter J.C., Johnson S., and Rees D.C. J. Med. Chem. 32 (1989) 1620
20. Snow R.J., Abeywardane A., Cambell S., Lord J., Kashem M.A., Khine H.H., King J., Kowalski J.A., Pullen S.S., Roma T., Roth G.P., Sarko C.R., Wilson N.S., Winters M.P., Wolak J.P., and Cywin C.L. Bioorg. Med. Chem. Lett. 17 (2007) 3660
21. Brennan T.J., Vandermeulen E.P., and Gebhart G.F. Pain 64 (1996) 493
22. Obach R.S., Baxter J.G., Liston T.E., Silber M., Jones B.C., Macintyre F., Rance D.J., and Wastall P. J. Pharmacol. Exp. Ther. 283 (1997) 46